Hill-Rom (HRC) Updates FY19 Earnings Guidance

Hill-Rom (NYSE:HRC) issued an update on its FY19 earnings guidance on Friday morning. The company provided earnings per share guidance of $5.02-5.06 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.05. The company issued revenue guidance of +2-3% to approximately $2.90-2.93 billion, compared to the consensus revenue estimate of $2.88 billion.Hill-Rom also updated its FY 2019 guidance to $5.02-5.06 EPS.

NYSE HRC opened at $97.13 on Friday. Hill-Rom has a one year low of $81.82 and a one year high of $108.68. The company has a quick ratio of 1.25, a current ratio of 1.70 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $6.40 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.66 and a beta of 0.95.

Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, April 26th. The medical technology company reported $1.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.03. Hill-Rom had a net margin of 7.21% and a return on equity of 21.23%. The business had revenue of $714.20 million during the quarter, compared to analyst estimates of $705.59 million. During the same period in the previous year, the business posted $1.05 EPS. The company’s quarterly revenue was up .5% on a year-over-year basis. Equities analysts forecast that Hill-Rom will post 5.04 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 22nd were issued a $0.21 dividend. The ex-dividend date of this dividend was Thursday, March 21st. This is a positive change from Hill-Rom’s previous quarterly dividend of $0.20. This represents a $0.84 annualized dividend and a dividend yield of 0.86%. Hill-Rom’s payout ratio is 17.68%.

A number of research firms have issued reports on HRC. ValuEngine lowered shares of Hill-Rom from a buy rating to a hold rating in a research note on Thursday, April 18th. Zacks Investment Research raised shares of Hill-Rom from a hold rating to a buy rating and set a $118.00 target price for the company in a research note on Tuesday, April 16th. Barclays boosted their target price on shares of Hill-Rom from $103.00 to $108.00 and gave the company an equal weight rating in a research note on Monday, April 15th. Finally, Needham & Company LLC reissued a buy rating and set a $116.00 target price on shares of Hill-Rom in a research note on Monday, March 11th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $109.88.

COPYRIGHT VIOLATION WARNING: This news story was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2019/04/26/hill-rom-hrc-updates-fy19-earnings-guidance.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Read More: What defines an oversold asset?

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.